Tiziana Life Sciences receives Nasdaq deficiency notice

Tiziana Life Sciences disclosed the receipt of a notice on July 19, 2023 from the Nasdaq Stock Market LLC that the company is not currently in compliance with the $1.00 Minimum Bid Price Requirement for continued listing of the company’s common shares on the Nasdaq Capital Market, as set forth in Nasdaq Listing Rule 5450(a)(1). The Notice indicated that, consistent with Nasdaq Listing Rule 5810(c)(3)(A), the Company has 180 days, or until January 16, 2024, to regain compliance with the Minimum Bid Price Requirement by having the closing bid price of the company’s ordinary share’s meet or exceed $1.00 per ordinary share for at least ten consecutive business days. The Notice is only a notification of deficiency, not of imminent delisting, and has no current effect on the listing or trading of the company’s securities on the Nasdaq Capital Market. Tiziana intends to monitor the closing bid price of its common shares and may, if appropriate, consider implementing available options to regain compliance with the Minimum Bid Price Requirement. If the company does not regain compliance by the Compliance Deadline, the company may be afforded an additional 180 calendar day period to regain compliance. The company intends to resolve the deficiency and regain compliance with the Listing Rules.